AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 282 min read$RGEN

Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong Earnings

Wasatch Global Investors' Q3 2026 letter noted Repligen (RGEN) as a top performer. RGEN, a biotech firm, saw gains from strong earnings and biotech sector momentum. Shares closed at $175.80, down 4.86% monthly but up 18.40% yearly. The company beat Q2 earnings estimates and raised full-year guidance.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 2:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 2:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong Earnings — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RGENBullishHigh
01

Why it matters

The earnings beat and guidance raise provide fresh, material information that can drive short‑term buying interest in RGEN.

02

Market read

Repligen's earnings beat and guidance lift are likely to boost its stock and positively influence the biotech small‑cap space.

03

What to watch

Potential headwinds from AI‑related speculative stocks could limit upside for Repligen.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Wasatch Global Investors' Q3 2026 Small Cap Growth Strategy outperformed the Russell 2000 Growth Index, citing Repligen as a key contributor due to its strong earnings.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Wasatch Small Cap Growth Strategy highlighted Repligen as a top contributor after it reported Q2 earnings that beat estimates and raised full-year guidance.

Expected impact

upward pressure as investors price in the earnings beat and higher guidance

Evidence & confidence

The fund letter cites concrete earnings beat and guidance lift, which are fresh, material facts for a mid‑cap biotech.

Market effects

Sector

Positive for the broader biotech and bioprocessing sector as earnings beat may lift peers.

Regional

U.S. small‑cap growth funds may see increased allocation to biotech names.

Global

Limited to investors tracking U.S. biotech and related small‑cap funds.

Counterpoint

What could challenge this read

If the earnings beat was already priced in, the stock could face a short‑term pullback.

Key entities

  • company
    Repligen Corporation

    Bioprocessing technology provider that beat Q2 earnings and raised guidance.

  • asset_manager
    Wasatch Global Investors

    Manager of the Small Cap Growth Strategy that highlighted Repligen.

Read at source← All news

StoryRepligen reports record Q3 revenue, completes BioLife acquisition and raises FY‑2026 guidance

Also covered by

6 outlets

Related articles

OCT 27
$RGENHigh

Repligen Corp (RGEN) Q3 2026 Earnings Call Highlights: Record Revenue, Raised Guidance

Repligen Corp (RGEN) reported Q3 2026 revenue of $209M, up 12.5% organically, and raised 2026 guidance. Chromatography and proteins grew over 40%, while filtration declined 11%. BioLife acquisition is expected to be $0.05 accretive in 2027. Capital equipment orders increased mid-teens YoY, but revenue lags due to slow customer decisions. Inflationary pressures and product mix headwinds impacted margins. The company recorded a $41M intangible asset impairment.

finance.yahoo.com2 min
OCT 27
$RGENMedAI 8/10

Repligen Corporation Q3 2026 Earnings Call Summary

Repligen Corporation reported Q3 2026 revenue of $209M, up 12.5% organically, driven by proteins and chromatography. Capital equipment orders hit a 5-year high, but revenue declined due to delayed deliveries. The BioLife acquisition is expected to be $0.05 accretive to 2027 earnings. Management forecasts 2027 revenue exceeding $1B and narrowed 2026 organic growth to 12%-13%. China grew over 40%, and the Analytics franchise set records.

finance.yahoo.com2 min
OCT 27
$RGENMedAI 8/10

Repligen (RGEN) Q3 2026 Earnings Call Transcript

Repligen reported $209M in Q3 2026 revenue, up 12.5% organically, with expanded margins. The company raised full-year guidance, including $24M from BioLife acquisition. Capital equipment orders rose mid-teens YoY, and services grew over 20%. Biopharma drove growth, while CDMOs declined. Repligen expects to exceed $1B in revenue in 2027, with Asia Pacific showing strong growth.

finance.yahoo.com2 min
OCT 27
$RGENMedAI 8/10

What Repligen (RGEN) Said on Its Q3 Earnings Call

Repligen (RGEN) reported Q3 earnings, noting BioLife acquisition will be slightly dilutive to Q4 earnings but expects $0.05 EPS accretion by 2027. Equipment orders rose mid-teens YoY, with a strong backlog for 2027. Filtration revenue fell 11%, while consumables and services grew over 20%. Chromatography and proteins revenue surged over 50% and 40%, respectively. Adjusted EPS rose 15% to $0.53. Repligen expects 2027 revenue growth of at least 25%, exceeding $1B.

finance.yahoo.com2 min